Azithromycin blocks autophagy and may predispose cystic fibrosis patients to mycobacterial infection by Renna, M et al.
Research article
3554	 The	Journal	of	Clinical	Investigation	 	 	 http://www.jci.org	 	 	 Volume 121	 	 	 Number 9	 	 	 September 2011
Azithromycin blocks autophagy  
and may predispose cystic fibrosis  
patients to mycobacterial infection
Maurizio Renna,1 Catherine Schaffner,2 Karen Brown,2,3 Shaobin Shang,4  
Marcela Henao Tamayo,4 Krisztina Hegyi,2 Neil J. Grimsey,2 David Cusens,2,3 Sarah Coulter,2 
Jason Cooper,1 Anne R. Bowden,2 Sandra M. Newton,5 Beate Kampmann,5 Jennifer Helm,6 
Andrew Jones,6 Charles S. Haworth,3 Randall J. Basaraba,4 Mary Ann DeGroote,4  
Diane J. Ordway,4 David C. Rubinsztein,1 and R. Andres Floto2,3
1Department of Medical Genetics and 2Department of Medicine, Cambridge Institute for Medical Research, University of Cambridge,  
Cambridge, United Kingdom. 3Adult Cystic Fibrosis Centre, Papworth Hospital, Cambridge, United Kingdom. 4Department of Microbiology,  
Immunology, and Pathology, Colorado State University, Fort Collins, Colorado, USA. 5Wellcome Centre for Clinical Tropical Medicine,  
Imperial College London, London, United Kingdom. 6Adult Cystic Fibrosis Unit, Wythenshawe Hospital, Manchester, United Kingdom.
Azithromycin	is	a	potent	macrolide	antibiotic	with	poorly	understood	antiinflammatory	properties.	Long-
term	use	of	azithromycin	in	patients	with	chronic	inflammatory	lung	diseases,	such	as	cystic	fibrosis	(CF),	
results	in	improved	outcomes.	Paradoxically,	a	recent	study	reported	that	azithromycin	use	in	patients	with	
CF	is	associated	with	increased	infection	with	nontuberculous	mycobacteria	(NTM).	Here,	we	confirm	that	
long-term	azithromycin	use	by	adults	with	CF	is	associated	with	the	development	of	infection	with	NTM,	
particularly	the	multi-drug-resistant	species	Mycobacterium abscessus,	and	identify	an	underlying	mechanism.	
We	found	that	in	primary	human	macrophages,	concentrations	of	azithromycin	achieved	during	therapeutic	
dosing	blocked	autophagosome	clearance	by	preventing	lysosomal	acidification,	thereby	impairing	autopha-
gic	and	phagosomal	degradation.	As	a	consequence,	azithromycin	treatment	inhibited	intracellular	killing	of	
mycobacteria	within	macrophages	and	resulted	in	chronic	infection	with	NTM	in	mice.	Our	findings	empha-
size	the	essential	role	for	autophagy	in	the	host	response	to	infection	with	NTM,	reveal	why	chronic	use	of	
azithromycin	may	predispose	to	mycobacterial	disease,	and	highlight	the	dangers	of	inadvertent	pharmaco-
logical	blockade	of	autophagy	in	patients	at	risk	of	infection	with	drug-resistant	pathogens.
Introduction
Azithromycin is a potent antibiotic and is frequently used in pro-
phylaxis and treatment regimens for mycobacterial infections (1). 
Long-term use of azithromycin and other macrolide antibiotics 
has increased as a result of reports of improved clinical outcomes 
in patients with cystic fibrosis (CF) (2), chronic obstructive pul-
monary disease (3), panbronchiolitis (4), asthma (5), and chronic 
transplant rejection (6). These benefits are believed to result from 
its antiinflammatory effects on macrophages and neutrophils 
mediated through unknown mechanisms (7).
Worryingly, several studies have identified a synchronous 
increase in mycobacterial infection of CF patients, predominant-
ly with the multi-drug-resistant, highly pathogenic nontubercu-
lous mycobacteria (NTM) Mycobacterium abscessus (8, 9), for which 
there is no reliable treatment (1). We therefore wondered wheth-
er azithromycin paradoxically impairs host immunity against 
mycobacteria. Macroautophagy (referred to herein as autophagy) 
appears crucial for an effective cellular response against mycobac-
teria (10). Since the macrolide bafilomycin disrupts autophagy in 
vitro (11), we examined whether azithromycin blocks autophagy 
and thereby impairs intracellular killing of NTM. Here we pres-
ent clinical data suggestive of an association between long-term 
azithromycin treatment and development of NTM infection in CF 
patients. At concentrations achieved during therapeutic dosing, 
azithromycin impaired lysosomal degradation of both autopha-
gosomes and phagosomes and led to failure of intracellular kill-
ing of mycobacteria and development of chronic infection with 
M. abscessus in mouse models.
Results
Long-term azithromycin use may predispose CF patients to NTM infection. 
Escalating azithromycin use over the last 5 years has mirrored an 
increase in patients colonized or infected with NTM in our adult 
CF center (Figure 1A), not explicable by changes in sputum sam-
pling (Supplemental Table 1; supplemental material available 
online with this article; doi:10.1172/JCI46095DS1) or micro-
bial culture methods. Long-term azithromycin use was associ-
ated with developing infection with NTM, particularly M. abscessus 
(P = 0.0009, 2-tailed uncorrected χ2; Figure 1B). When adjusted for 
age — which was identified, as in previous studies (9), as a signifi-
cant covariate (P = 0.01; Supplemental Table 2) — azithromycin use 
remained significantly associated with NTM disease (P = 0.00046; 
odds ratio 9.80, 95% CI 2.09–45.87). Similar associations of chron-
ic azithromycin use with NTM infection have been reported for 
an Israeli CF cohort (12), which suggests that azithromycin might 
impair host immunity against mycobacteria.
Azithromycin blocks autophagosome degradation. Since autophagy 
appears crucial for an effective cellular response against mycobac-
teria (10), we investigated whether azithromycin blocks autopha-
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gy, thereby preventing autophagy-dependent intracellular killing 
of NTM. Autophagy is routinely assayed by quantifying autopha-
gosomes, achieved either by measuring levels of LC3-II, a protein 
that specifically associates with autophagosomes, or by detection 
of LC3-II+ vesicles (13). In cell lines, azithromycin caused a dose-
dependent increase in both the number of LC3+ vesicles and the 
amount of LC3-II protein (EC50, 4.5 μg/ml; Figure 1, C and D). 
This suggests an accumulation of autophagosomes, which could 
result from either their increased synthesis or their decreased deg-
radation. We therefore examined the effect of azithromycin in the 
presence of the lysosomal inhibitor bafilomycin A1 (BafA1), which 
blocks LC3-II destruction (11). Cotreatment of azithromycin and 
BafA1 resulted in no significant increase in LC3-II levels compared 
with BafA1 alone (Figure 1E), which indicates that azithromycin 
does not induce autophagosome synthesis, but rather blocks LC3-II 
degradation. Moreover, the azithromycin-induced rise in LC3-II 
was not accompanied by decreases in mTOR-dependent signaling 
(monitored by phosphorylation of p70S6 kinase and S6), a major 
negative regulator of autophagosome synthesis (14), but was 
associated — in both HeLa cells and primary macrophages — with 
Figure 1
Azithromycin blocks autophagy by impairing autophagic flux. (A) At Papworth Hospital, the numbers of adult CF patients on long-term azithro-
mycin (AZM; red) and with new sputum cultures positive for NTM (gray) rose over the last 5 years. (B) Analysis of the 2007–2008 CF patient 
cohort. In patients currently or previously infected with NTM, long-term azithromycin use (current or within 6 months of first NTM culture) was 
significantly more common that in uninfected patients (P = 0.0009; 2-tailed uncorrected χ2). (C) In GFP-LC3+ COS7 cells, 24-hour treatment 
with azithromycin increased the number of cells containing 10 or more GFP-LC3+ vesicles more so than rapamycin (200 nM). (D) In HeLa cells, 
azithromycin caused a dose-dependent increase in LC3-II levels (EC50, 4.5 μg/ml). exp., exposure. (E) In the presence of 400 nM BafA1, azithro-
mycin treatment of HeLa cells did not increase LC3-II compared with BafA1 alone. (F) Azithromycin treatment (16 μg/ml) of HeLa cells, while 
increasing LC3-II, did not alter mTOR-dependent signaling (monitored by changes in phosphorylation of S6 and p70S6 kinase); however, it did 
increase p62 levels. (G) Azithromycin dose-dependently increased LC3-II and p62 levels in primary human macrophages. (H) Similar effect of 
azithromycin, assessed by LC3-II and p62 levels, in primary macrophages derived from clinically stable CF patients and healthy controls (n = 3 
per group). *P < 0.05; **P < 0.005.
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elevations in the endogenous autophagy substrate p62 (ref. 15 and 
Figure 1, F and G). Azithromycin treatment in vitro resulted in 
accumulation of LC3-II and p62 in primary macrophages from CF 
patients similar to that in cells from healthy controls (Figure 1H 
and Supplemental Figure 1).
To confirm that azithromycin blocks autophagy-mediated 
degradation at, or below, concentrations achieved in clinical 
practice (between 12 μg/ml and 53 μg/ml in sputum, but several 
hundred–fold higher in phagocytic cells; refs. 7, 16), we exam-
ined the clearance of 2 known autophagy substrates: mutant 
(Q74) huntingtin (17) and A53T α-syncuclein (18). Azithromycin 
treatment retarded the basal and rapamycin-enhanced degrada-
tion of A53T α-synuclein and led to enhanced accumulation of 
intracellular aggregates of Q74 huntingtin (Figure 2, A and B). 
We next examined whether inhibition of LC3-II clearance by 
azithromycin was caused by failure of autophagosome-lysosome 
fusion, as seen with long-term treatment with BafA1 treatment 
(11), or failure of lysosomal function, a mechanism we recently 
reported (19). Confocal microscopy of HeLa cells coexpressing 
mCherry-LC3 and the lysosomal marker lgp120 revealed that 
although the number of LC3+ vesicles per cell increased with rapa-
mycin, BafA1, or azithromycin treatment, the degree of LC3 colo-
calization with lgp120 was not significantly affected by azithro-
mycin, but was, as expected, enhanced by rapamycin and inhibited 
by BafA1 (Figure 3A). However, azithromycin prevented acidifi-
cation of autophagosomes. In HeLa cells stably expressing the 
mCherry-GFP-LC3 reporter, azithromycin treatment significantly 
increased nonacidified autophagosomes (i.e., mCherry+GFP+) and 
reduced acidified autophagosomes (mCherry+GFP–; Figure 3B).
Azithromycin disrupts autophagosome and phagosome function in 
macrophages. Since intracellular killing of mycobacteria by macro-
phages is critically enhanced by IFN-γ–induced autophagy (20), 
we examined the effect of azithromycin on autophagosomal flux 
triggered by this cytokine. Azithromycin blocked IFN-γ–induced 
as well as basal autophagosomal acidification in macrophages 
(Figure 4A), suggestive of impaired lysosomal function. Direct 
quantification of lysosomal pH, achieved by preloading human 
primary macrophages with dextran double-labeled with acid-
sensitive (FITC) and resistant (TMR) fluorophores (21), indicat-
ed that 4 hours of treatment with azithromycin was sufficient 
to trigger significant alkalinization of lysosomes (Figure 4B). 
Azithromycin also blocked the acidification of phagosomes con-
taining mycobacteria (Figure 4C and Supplemental Figure 2) 
or latex beads (Supplemental Figure 3). Using heat-killed 
M. abscessus labeled with both acid-quenchable (FAM) and pH 
stable (Alexa Fluor 633) fluorophores to report compartmental 
pH, we found that azithromycin pretreatment resulted in signif-
icant alkalinization of mycobacterial phagosomes (Figure 4C), 
to pH levels inhibitory to most lysosomal proteases. Similar 
azithromycin-induced phagosomal alkalinization was observed for 
cells ingesting PFA-killed M. tuberculosis (Supplemental Figure 2). 
As expected, azithromycin significantly reduced phagosomal 
protein degradation, as measured by time-dependent loss of sur-
face-bound OVA from internalized latex beads (Figure 5A and 
Supplemental Figure 4). Although significant, phagosome-lyso-
some fusion was only impaired to a small extent by azithromycin 
(Figure 5B). Thus, it is likely that the block in phagosomal degra-
dation results predominantly from a direct effect of azithromycin 
on compartmental pH. Azithromycin also reduced TNF-α release 
from macrophages in response to particulate but not soluble 
Figure 2
Azithromycin blocks autophagic clearance and autophagosome acidifi-
cation. (A) Azithromycin reduced basal (black) and rapamycin-induced 
(gray) clearance of mutant (A53T) α-synuclein in stable inducible PC12 
cells. The A53T α-synuclein transgene was induced with doxycycline 
for 48 hours and then switched off (by antibiotic removal) before cells 
were treated with vehicle alone, rapamycin (200 nM), and/or azithro-
mycin for a further 24 hours. (B) Azithromycin reduced clearance of 
mutant (Q74) huntingtin. Aggregates of GFP-Q74 huntingtin were 
reduced by rapamycin treatment, but increased when autophagy was 
blocked by either BafA1 or azithromycin (4–16 μg/ml). Con, control. 
*P < 0.05; **P < 0.005. Scale bar: 10 μm.
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stimuli (Supplemental Figure 5), which suggests an inhibition 
of phagosome-triggered cytokine release. These data suggest that 
azithromycin treatment might compromise the host response 
to mycobacterial infection both by preventing degradation of 
mycobacteria within autophagosomes and phagosomes and by 
disrupting release of cytokines, such as TNF-α, that promote 
autophagy-dependent intracellular killing of mycobacteria.
Intracellular killing of mycobacteria is impaired by azithromycin. We 
therefore examined the effect of azithromycin on the survival of 
mycobacteria within primary human macrophages. Autophagy 
is critical for intracellular killing of M. tuberculosis and M. bovis 
BCG (10, 20), but also pathogenic NTM, including M. abscessus 
(Supplemental Figure 6). Over a wide range of concentrations, 
azithromycin blocked basal intracellular killing of M. bovis BCG 
and M. abscessus, as well as preventing the ability of the autophagy 
inducer rapamycin to enhance killing (Figure 6, A and B). The 
control of M. tuberculosis and NTM infection in vivo is crucially 
dependent on the inflammatory cytokines IFN-γ and TNF-α, 
which enhance intracellular killing of mycobacteria through the 
induction of autophagy (10). As expected, azithromycin treatment 
Figure 3
Azithromycin blocks acidification of autophagosomes without impairing lysosomal function. (A) Azithromycin did not impair autophagosome-
lysosome fusion. Confocal microscopy of HeLa cells coexpressing LC3-mCherry with the lysosomal marker lgp120-GFP revealed that although 
rapamycin, BafA1, and azithromycin (16 μg/ml) treatment increased the total number of LC3+ vesicles per cell, the colocalization of LC3+ vesicles 
with lgp120 (LC3+/lgp120+) was not significantly different from controls after azithromycin treatment, but increased with rapamycin and decreased 
with BafA1 treatment. (B) Azithromycin impaired autophagosome acidification. HeLa cells stably expressing the mCherry-GFP-LC3 construct 
were treated with either 8–16 μg/ml azithromycin or BafA1 for 24 hours and analyzed by confocal microscopy. Compared with the control, azithro-
mycin caused a significant reduction in the number of acidified LC3+ vesicles, but increased total LC3+ vesicles per cell. Number of vesicles was 
normalized to control cells. **P < 0.005. Scale bars: 10 μm.
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significantly blocked IFN-γ– and TNF-α–dependent killing of 
M. abscessus in primary human macrophages (Figure 6C). Further-
more, inoculation of whole blood with M. abscessus revealed that 
azithromycin pretreatment, while resulting in dose-dependent 
killing of presumably extracellular bacteria, blocked the ability 
of the autophagy inducers rapamycin and IFN-γ to enhance the 
clearance of mycobacteria (Figure 6D). These data suggest that 
the effect of azithromycin on NTM infection in vivo will depend 
on a balance between its direct antibiotic effects and its ability to 
enhance intracellular survival of mycobacteria through block of 
autophagosomal and phagosomal degradation.
Azithromycin promotes chronic infec-
tion with M. abscessus in vivo. Although 
frequently sensitive to azithromycin 
in vitro, M. abscessus becomes highly 
macrolide resistant in vivo (Figure 6E) 
through inducible expression of the 
ribosomal methyltransferase erm(41) 
(22), equivalent to erm(37) found in 
M. tuberculosis, as well as through for-
mation of a protective biofilm (23). 
To examine the effect of azithromy-
cin treatment on the host response to 
mycobacteria in vivo, we infected mice 
via aerosol challenge with azithromy-
cin-resistant M. abscessus (Figure 7). As 
previously described (24), lung infec-
tion in control mice peaked at day 15, 
with clearance of mycobacteria and 
resolution of peribronchiolar inflam-
matory infiltrates by day 30. In con-
trast, azithromycin treatment led to 
persistent lung infection associated 
with extensive granulomatous inflam-
mation and failure of macrophage 
degradation of intracellular mycobac-
teria (Figure 7, A–C). As anticipated, 
azithromycin also influenced pul-
monary cytokine levels during infec-
tion (Figure 7D). Lung macrophages 
(defined as CD11bhi) and dendritic 
cells (CD11b–CD11chiDEC205hi) pro-
duced less TNF-α and IL-12, whereas 
CD4+ and CD8+ effector T cells gener-
ated more IL-4 and less IFN-γ; the rea-
sons for this are unclear, but may be associated with altered antigen 
presentation. This cytokine environment within the lung would 
be expected to further inhibit autophagic killing by macrophages 
(25, 26). These findings indicate that the ability of azithromycin to 
inhibit autophagy may outweigh any direct bactericidal properties 
and lead to chronic infection with NTM in vivo, explaining our own 
clinical observation and those of others (12).
Discussion
We found that azithromycin blocked lysosomal degradation of 
autophagosomes and phagosomes, which, while potentially con-
Figure 4
Azithromycin blocks autophagosome and phagosome acidification by impairing lysosomal function. (A) Prevention of IFN-γ–induced autophagic 
flux. RAW 264.7 cells stably expressing mRFP-GFP-LC3 were treated with vehicle alone (as control), BafA1 (200 nM), azithromycin (40 μg/ml), 
IFN-γ (200 ng/ml), or azithromycin plus IFN-γ. Representative images are shown. Quantification of acidified (mCherry+GFP–; red) and nonacidi-
fied (mCherry+GFP+; green) vesicles revealed a significant reduction in basal and IFN-γ–induced autophagosomal acidification by azithromycin 
treatment. (B) Reduced acidification of lysosomes in primary human macrophages. Double-labeled (FITC and TMR) dextran was loaded into 
lysosomes before cells were treated for 4 hours with azithromycin (80 μg/ml) or BafA1 (400 nM). As determined by confocal fluorescence analy-
sis, azithromycin significantly reduced lysosomal acidification compared with controls, as did BafA1. Intracellular pH calibrations were performed 
as described in Supplemental Methods. (C) Azithromycin decreased acidification of phagosomes containing M. abscessus. Patient-derived 
M. abscessus strains were heat-killed, double-labeled with FAM and Alexa Fluor 633, and incubated for 24 hours with primary human mac-
rophages untreated or treated with azithromycin (20 μg/ml) or BafA1 (100 nM). Representative confocal/DIC images of macrophages with 
intracellular labeled M. abscessus show increased mycobacterial FAM fluorescence (indicating reduced acidification) after treatment with 
azithromycin or BafA1. Also shown is quantification by flow cytometry of FAM fluorescence of macrophages that have internalized M. abscessus 
(i.e., Alexa Fluor 633+). Corresponding phagosomal pH values (see Supplemental Methods) demonstrated significant alkalinization of phago-
somes with azithromycin or BafA1 treatment. Scale bars: 10 μm.
Figure 5
Azithromycin blocks phagosomal degradation and phagosome-lysosome fusion. (A) OVA-coated 
beads were incubated with primary human macrophages (1-hour pulse, 23-hour chase). Internal-
ized beads were released, and the amount of OVA coating was quantified by flow cytometry after 
incubation with fluorescent anti-OVA antibody. Treatment with azithromycin (20 μg/ml) significantly 
reduced OVA degradation compared with untreated cells, to levels close to those achieved by BafA1 
(100 nM) or leupeptin/pepstatin. (B) Human primary macrophages were incubated (1-hour pulse, 4-hour 
chase) with TMR- and biotin-conjugated dextran to load lysosomes and then fed with IgG-coated 
streptavidin-conjugated fluorescent latex beads (30-minute pulse, 2-hour chase) with no treatment or 
in the presence of azithromycin (80 μg/ml) or BafA1 (400 nM). Beads were recovered by cell disrup-
tion, and the degree of bound dextran fluorescence was quantified by flow cytometry. Shown are a 
representative histogram and average geometric mean fluorescence of triplicate samples.
Downloaded from http://www.jci.org on July 14, 2016.   http://dx.doi.org/10.1172/JCI46095
research article
3560	 The	Journal	of	Clinical	Investigation   http://www.jci.org   Volume 121   Number 9   September 2011
tributing to its antiinflammatory effects seen clinically, impaired 
intracellular killing of mycobacteria and promoted chronic infec-
tion with NTM in vivo. Infection of CF patients with the multi-
drug-resistant NTM M. abscessus is a growing clinical problem, 
leading to accelerated deterioration in lung function despite 
aggressive antibiotic therapy (8, 9). Previous epidemiological stud-
ies (12) and our current analysis suggest an association between 
long-term azithromycin use and development of M. abscessus infec-
tion, although definitive proof will require a prospective multi-
center study with standardized sputum sampling and culture 
methods. Our findings provide a plausible mechanism for how 
chronic azithromycin use might predispose to NTM infection in 
CF patients and raise potential concerns about long-term macro-
lide treatment for other inflammatory lung diseases, use of mac-
rolides in population-based eradication programs for trachoma 
and other infectious diseases (27), and clinical introduction of 
nonantibiotic macrolides as antiinflammatory agents.
The net effect of azithromycin during clinical NTM infection 
will depend on the balance between its direct antibiotic effect and 
its ability to block intracellular killing of mycobacteria. For slow-
growing NTM species, such as the M. avium-intracellulare complex 
(MAC), which do not possess inducible macrolide resistance genes, 
azithromycin therapy (as part of multi-drug regimens) is usually 
highly effective. Whether it remains so during long-term, low-dose, 
intermittent treatment is unclear, particularly when concentra-
tions of macrolides within MAC-containing phagosomes are likely 
to be reduced in vivo to below bacteriostatic levels (28). For rapid-
growing NTM species, such as M. abscessus, that can acquire mac-
rolide resistance (Figure 6E) through rapid induction of erm(41), 
single amino acid ribosomal mutation (1), and biofilm formation 
(23), the likely effect of long-term azithromycin therapy will be to 
promote infection, as seen in our mouse infection model. Azithro-
mycin treatment also influenced cytokine production in vitro and 
in vivo, leading to reduced levels of macrophage- and dendritic 
cell–derived IL-12 and TNF-α and skewing T cell responses away 
from IFN-γ and toward IL-4. Although the mechanism underlying 
these effects remains to be elucidated, the net result will likely be 
further inhibition of autophagic killing (25, 26).
We demonstrated that azithromycin blocked autophagy in 
primary macrophages from stable CF patients as effectively 
as in those from healthy controls. Although basal levels of the 
autophagy substrate p62 were lower in CF macrophages, poten-
tially as a result of transcriptional regulation (11), its levels were 
increased in both control and CF cells by azithromycin, indicative 
of blocked autophagic clearance.
Although the ability of azithromycin to block autophagy could 
be clinically exploitable in anticancer therapy, where tumor suscep-
tibility to chemotherapy may be enhanced (29), our data suggest 
Figure 6
Azithromycin blocks intracellular killing of mycobacteria. (A and B) Human macrophages were infected with luminescent mycobacteria — 
M. bovis BCG (A) and M. abscessus (B) — for 2 hours, washed, and exposed to the indicated concentrations of azithromycin (μg/ml) and/or 200 nM 
rapamycin for 24 hours. Viable intracellular mycobacteria were then assessed by measuring cell-associated luminescence after cell lysis. (C) 
IFN-γ and TNF-α enhanced intracellular killing of M. abscessus in human macrophages, and this was blocked by azithromycin pretreatment. 
Results were normalized to levels obtained without cytokine addition. (D) Patient-derived M. abscessus strains were incubated with peripheral 
blood from healthy subjects pretreated for 24 hours with vehicle alone or increasing concentrations of azithromycin. After 72 hours of incuba-
tion at 37°C, viable mycobacteria were quantified after sample lysis by counting CFUs. Addition of azithromycin, while reducing mycobacterial 
growth (white), prevented any additional autophagy-dependent killing achieved by coincubation with IFN-γ (200 U/ml) or rapamycin (100 nM). 
(E) Induction of macrolide resistance in M. abscessus. M. abscessus-lux was grown for 6 days in liquid culture (i.e., Middlebrook 7H9 plus ADC 
enrichment) in the presence of 0.1 μg/ml azithromycin or vehicle alone, washed, and resuspended in RPMI with 10% FCS with the indicated 
concentrations of azithromycin. Viable mycobacteria were assessed by measuring luminescence after 24 hours. *P < 0.05; **P < 0.005.
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that its impairment of autophagic degradation in macrophages 
will compromise host immunity to mycobacteria and potentially 
block the efficacy of adjuvant IFN-γ therapy often used in patients 
with difficult NTM or M. tuberculosis infection. Our findings have 
profound implications for the treatment of multi-drug-resistant 
mycobacteria, including M. tuberculosis, in which the ability of 
azithromycin to block intracellular bacterial killing is not accom-
panied by a direct antibiotic effect.
Methods
Further information can be found in Supplemental Methods.
Culture of cell lines and generation of human macrophages
HeLa and COS-7 cells were grown as previously described. Human mono-
cyte-derived macrophages were isolated from peripheral blood as previ-
ously described (30), obtained from healthy consented subjects (approved 
by Regional NHS Research Ethics Committee), or from patients with CF 
(clinically stable and not taking azithromycin).
Lysosomal and phagosomal pH measurements
Human primary macrophages were loaded with TMR-FITC dextran (1-hour 
pulse, 4-hour chase). Cells were then treated with compounds and visu-
alized by live cell fluorescence/differential interference contrast (fluores-
cence/DIC) confocal imaging. To determine the phagosomal pH, primary 
macrophages were incubated (1-hour pulse, 23-hour chase) with albumin-
coated, FAM-conjugated 645-nm (Far Red) latex beads, patient-derived 
heat-killed M. abscessus strains double-labeled with FAM and Alexa Fluor 
633, or PFA-killed M. tuberculosis H37Rv double-labeled with FITC and 
Alexa Fluor 633. Macrophages were pretreated for 24 hours with com-
pounds. Analysis was carried out by either live cell fluorescence/DIC con-
focal imaging or flow cytometry, in which the fluorescence of cells with 
internalized particles (FarRed or Alexa Fluor 633 for beads and mycobac-
teria, respectively) was measured. Intracellular calibration was achieved as 
detailed in Supplemental Methods.
Phagosomal degradation assays
Human macrophages were incubated (30-minute pulse, 2-hour chase) 
with OVA-conjugated fluorescent latex beads at 4°C, 37°C, or 37°C with 
15-minute protease inhibitor pretreatment. Macrophages were pretreated 
with BafA1 or azithromycin for 24 hours prior to phagocytosis; treatment 
continued throughout the experiment. Beads were then recovered by cell 
disruption in the presence of proteases inhibitors, then incubated with 
OVA-specific biotinylated antibody and fluorescent streptavidin, which 
was quantified by flow cytometry.
Figure 7
Azithromycin promotes M. abscessus infection in vivo. (A) C57BL/6 mice were infected by aerosol challenge with azithromycin-resistant 
M. abscessus. Treatment with azithromycin (100 mg/kg) by gavage for 5 days per week resulted in failure of M. abscessus clearance from lungs. (B) 
Representative lung histology demonstrating that azithromycin treatment led to persistent lung infection associated with extensive granulomas (arrows) 
and peribronchiolar inflammation at day 30. Ziehl-Neelsen staining confirmed the presence of large numbers of intracellular mycobacteria in azithromy-
cin-treated, but not control, animals. Scale bars: 200 μm (histology); 10 μm (Ziehl-Neelsen). (C) Extent and severity of lung lesions in M. abscessus– 
infected mice at days 15 and 30 of treatment with vehicle alone or azithromycin. (D) Assessment of intracellular cytokine profiles for lung macro-
phages, dendritic cells, and CD4+ and CD8+ effector T cells during infection in the presence or absence of chronic azithromycin treatment.
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Phagosome-lysosome fusion assays
Human macrophages were incubated (1-hour pulse, 4-hour chase) with 
TMR- and biotin-conjugated dextran to load lysosomes and then fed 
IgG-coated, streptavidin-conjugated fluorescent latex beads (30-minute 
pulse, 2-hour chase) with no treatment or in the presence of azithromycin 
(80 μg/ml) or BafA1. Beads were recovered by cell disruption, the degree of 
bound fluorescent dextran was quantified by flow cytometry, and average 
geometric mean fluorescence was determined.
In vitro mycobacterial infection assays
Primary human macrophages. Macrophages were inoculated with myco-
bacteria (MOI 10:1) for 2 hours at 37°C, repeatedly washed, and then 
incubated for 24 hours at 37°C in the presence or absence of azithro-
mycin or rapamycin, as indicated. Cells were finally lysed, and lumines-
cence was measured.
Whole blood mycobacterial infection assays. Patient-derived M. abscessus 
strains were grown to log phase in Middlebrook 7H9 media. Heparinized 
peripheral blood from healthy consented subjects was inoculated with 
M. abscessus after pretreatment for 24 hours with vehicle alone or azithro-
mycin and incubated for 72 hours at 37°C. Viable mycobacteria were quan-
tified (CFU) on microbial plates. Where indicated, IFN-γ or rapamycin were 
added to blood at the time of infection with mycobacteria.
Induction of macrolide resistance in vitro. M. abscessus-lux was grown in liquid 
culture in the presence of 0.1 μg/ml azithromycin or vehicle alone, washed, 
and resuspended in RPMI with 10% FCS with the indicated concentrations 
of azithromycin. Viable mycobacteria were assessed by measuring lumines-
cence after 24 hours.
In vivo mycobacterial infection
Mice were challenged with M. abscessus as previously described (24). Control 
(saline) and azithromycin groups (n = 5 per group) were treated 5 days per 
week at a concentration of 100 mg/kg by gavage. On days 15 and 30 after 
infection, bacterial loads in the lungs and spleen were determined by his-
tological and flow cytometry analysis (see Supplemental Methods). Bacte-
rial counts were determined by plating serial dilutions of homogenates of 
lungs after 3–7 days.
Statistics
Densitometric analysis on the immunoblots was done by Image J soft-
ware. P values for the Cellomics array scan counting and for other experi-
ments requiring multiple comparisons were determined by factorial 
ANOVA using STATVIEW software (version 4.53). P values for all other 
assays were determined using 2-tailed Student’s t test. A P value of 0.05 or 
less was considered significant. Experiments were performed on at least 3 
separate occasions with at least triplicate samples for each condition and 
represented as mean ± SD.
To test for an association between NTM status and azithromycin, we used 
a logistic regression model adjusted for covariates. Forward logistic regres-
sion was used to select covariates associated with NTM status (P < 0.05) from 
age, forced expiratory volume in 1 second, BMI, sex, colonization with Pseu-
domonas aeruginosa, CF-related liver disease, CF-related diabetes, CF-related 
asthma, allergic bronchopulmonary aspergillosis, and gastroesophageal 
reflux disease. Analyses were performed in R (http://www.r-project.org).
Study approval
All experimental protocols were approved by the Animal Care and Usage 
Committee of Colorado State University and complied with NIH guidelines.
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